Skip to main content
Translational Neuroscience logoLink to Translational Neuroscience
. 2020 Sep 11;11(1):334. doi: 10.1515/tnsci-2020-0142

Retraction of: Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia

Bertrand Fougère 1,2, Bruno Vellas 1,2, Gabor Abellan van Kan 1,2, Matteo Cesari 1,2
PMCID: PMC7724002  PMID: 33628470

The lead author and the publisher would like to inform that the article “Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia” (https://doi.org/10.1515/tnsci-2015-0009) has been retracted as per their request.

The article bears the hallmarks of plagiarism, using the unreferenced quotes from, among others, the following papers:

  1. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options – a mini-review. Gerontology. 2014;60(4):294–305.

  2. Bhasin S, He EJ, Kawakubo M, Schroeder ET, Yarasheski K, Opiteck G, et al. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J Clin Endocrinol Metab. 2009;94(11):4224–33. doi: 10.1210/jc.2009-1434.

  3. Ceglia L. Vitamin D and skeletal muscle tissue and function. Mol Aspects Med. 2008 Dec;29(6):407–14.

  4. Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, et al. International Working Group on Sarcopenia. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012;3(3):181–90. doi: 10.1007/s13539-012-0078-2.

  5. Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, et al. Frailty and sarcopenia: definitions and outcome parameters. Osteoporosis Int. 2012;23:1839–48. doi: 10.1007/s00198-012-1913-1.

  6. Cruz-Jentoft AJ, Michel JP, Cruz-Jentoft AJ, Michel J-P. Sarcopenia: a useful paradigm for physical frailty. Eur Geriatr Med. 2013;4(2):102–5.

  7. Drey M, Sieber CC, Bauer JM, Uter W, Dahinden P, Fariello RG, et al. C-terminal agrin fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction. Exp Gerontol. 2013;48(1):76–80. doi: 10.1016/j.exger.2012.05.021.

  8. Feng J, He W, Song Y, Wang Y, Simpson R, Zhang X, et al. Platelet-derived growth factor receptor beta: a novel urinary biomarker for recurrence of non-muscle-invasive bladder cancer. PLoS One. 2014;9(5):e96671. doi: 10.1371/journal.pone.0096671.

  9. Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, et al. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol. 2004;39(1):17–24. doi: 10.1016/j.exger.2003.09.012.

  10. Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4(1):19–29. doi: 10.1007/s13539-012-0079-1.

  11. Scharf G, Heineke J. Finding good biomarkers for sarcopenia. J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):145–8.


Articles from Translational Neuroscience are provided here courtesy of De Gruyter

RESOURCES